Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Abstract Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancie...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-04-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-024-00508-4 |
| _version_ | 1797199628684230656 |
|---|---|
| author | Wenjie Zhang Sumei Li Jinlan Long Shufeng Xie Minghui Wang Han Liu Zhenshu Xu |
| author_facet | Wenjie Zhang Sumei Li Jinlan Long Shufeng Xie Minghui Wang Han Liu Zhenshu Xu |
| author_sort | Wenjie Zhang |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancies (R/R BCM). Attempting to make CAR T-cells safer and more effective in treating R/R BCM, various novel engineered CAR T-cell agents are currently in the research and development or clinical trial stages. We have summarized here the latest reports on the novel CAR T-cell therapies for R/R BCM presented at the 2023 ASH Annual Meeting as well as the latest updates in related clinical trials. |
| first_indexed | 2024-04-24T07:18:47Z |
| format | Article |
| id | doaj.art-b1fbcb0aac43433bb57ee097a45ff9b1 |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-04-24T07:18:47Z |
| publishDate | 2024-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-b1fbcb0aac43433bb57ee097a45ff9b12024-04-21T11:11:34ZengBMCExperimental Hematology & Oncology2162-36192024-04-011311410.1186/s40164-024-00508-4Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meetingWenjie Zhang0Sumei Li1Jinlan Long2Shufeng Xie3Minghui Wang4Han Liu5Zhenshu Xu6Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalCollege of Chinese Traditional Medicine, Shandong University of Traditional Chinese MedicineFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalAbstract Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancies (R/R BCM). Attempting to make CAR T-cells safer and more effective in treating R/R BCM, various novel engineered CAR T-cell agents are currently in the research and development or clinical trial stages. We have summarized here the latest reports on the novel CAR T-cell therapies for R/R BCM presented at the 2023 ASH Annual Meeting as well as the latest updates in related clinical trials.https://doi.org/10.1186/s40164-024-00508-4CAR T-cell therapyRelapsed/refractory B-cell malignanciesASH 2023 |
| spellingShingle | Wenjie Zhang Sumei Li Jinlan Long Shufeng Xie Minghui Wang Han Liu Zhenshu Xu Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting Experimental Hematology & Oncology CAR T-cell therapy Relapsed/refractory B-cell malignancies ASH 2023 |
| title | Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting |
| title_full | Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting |
| title_fullStr | Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting |
| title_full_unstemmed | Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting |
| title_short | Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting |
| title_sort | novel car t cell therapies for relapsed refractory b cell malignancies latest updates from 2023 ash annual meeting |
| topic | CAR T-cell therapy Relapsed/refractory B-cell malignancies ASH 2023 |
| url | https://doi.org/10.1186/s40164-024-00508-4 |
| work_keys_str_mv | AT wenjiezhang novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting AT sumeili novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting AT jinlanlong novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting AT shufengxie novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting AT minghuiwang novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting AT hanliu novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting AT zhenshuxu novelcartcelltherapiesforrelapsedrefractorybcellmalignancieslatestupdatesfrom2023ashannualmeeting |